Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2022 · 10-Q
Revenue$11.18M$11.18M+6.1% vs Q1 2021 Net Income-$1.39M-$1.39MN/M vs Q1 2021 EPS Diluted-$0.09-$0.09N/M vs Q1 2021 Operating Income-$1,291,999N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived-$177,484N/M Margins · derivedOperating margin-11.6%−8.5 pt vs Q1 2021
Net margin-12.4%−14.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end